Exact Sciences Corp. (NASDAQ:EXAS)
Stock Price:
$83.84
+0
(0%)
Updated
Jun 2, 2023 08:00 PM GMT+0000
| Market Cap | 15.13B |
|---|---|
| Revenue | 2.20B |
| Gross Profit | 1.60B |
| Shares Out | 180.48M |
| EPS (ttm) | -2.91 |
| PE Ratio | -29.2829 |
| Forward PE | -31.5767 |
| Dividend Rate (ttm) | 0.0000 |
| Dividend Yield | 0.0000 |
| Trading Day | Jun 2 |
|---|---|
| Last Price | $83.84 |
| Previous Close | $83.84 |
| Change ($) | 0 |
| Change (%) | 0% |
| Day's Open | 84.93 |
| Day's Range | 82.39 - 85.5 |
| Day's Volume | 1.48M |
| 52 Week Range | 29.27 - 85.82 |
About Exact Sciences Corp.
exact sciences is a molecular diagnostics company focused on colorectal cancer. the company has exclusive intellectual property protecting its non-invasive, molecular screening technology for the detection of colorectal cancer.
stool-based dna (sdna) technology is included in the colorectal cancer screening guidelines of the american cancer society and the u.s. multi-society task force on colorectal cancer.
for more information on exact sciences' noninvasive colon cancer screening test, visit cologuardtest.com.
News
Quick info
Country
United States
Industry
Diagnostic Imaging Centers
Sector
Health Care and Social Assistance
Employees
6,400
CEO
Kevin Conroy
Address
5505 Endeavor Lane
Madison
Wisconsin
53719
Madison
Wisconsin
53719
Phone
16082845700
Website
exactsciences.com
Ticker Symbol
EXAS
Exchange
NASDAQ Stock Exchange
Reporting Currency
USD
Exact Sciences Corp. income statements (2022) (USD)
| August 2022 | August 2022 | April 2022 | February 2022 | |
|---|---|---|---|---|
| Total Revenue | 521.64M | 521.64M | 486.57M | 1.77B |
| Cost of Revenue | 144.60M | 144.60M | 134.71M | 458.76M |
| Gross Profit | 377.04M | 377.04M | 351.87M | 1.31B |
| Research & Development | 106.08M | 106.08M | 102.25M | 385.65M |
| Selling General & Admin | 397.59M | 397.59M | 401.95M | 1.66B |
| Operating Expense | 674.63M | 674.63M | 663.56M | 2.60B |
| Operating Income | -152.99M | -152.99M | -176.99M | -835.47M |
| Other Income Expense Net | 0 | 0 | 0 | 0 |
| EBIT | -152.99M | -152.99M | -176.99M | -835.47M |
| Interest Income | 3.05M | 3.05M | 3.03M | 12.73M |
| Pretax Income | -167.81M | -167.81M | -182.95M | -842.51M |
| Income Tax | -1.75M | -1.75M | -2.02M | -246.88M |
| Minority Interest | 0 | 0 | 0 | 0 |
| Net Income | -166.06M | -166.06M | -180.94M | -595.63M |
| Net Income Basic | -166.06M | -166.06M | -180.94M | -595.63M |
Exact Sciences Corp. income statements (2021) (USD)
| November 2021 | July 2021 | May 2021 | February 2021 | |
|---|---|---|---|---|
| Total Revenue | 456.38M | 434.82M | 402.08M | 1.49B |
| Cost of Revenue | 115.74M | 113.97M | 109.99M | 354.32M |
| Gross Profit | 340.64M | 320.85M | 292.08M | 1.14B |
| Research & Development | 75.36M | 106.24M | 115.57M | 554.05M |
| Selling General & Admin | 383.16M | 362.46M | 453.87M | 1.07B |
| Operating Expense | 598.19M | 606.48M | 702.62M | 2.07B |
| Operating Income | -141.81M | -171.66M | -300.54M | -582.02M |
| Other Income Expense Net | 0 | 0 | 0 | 0 |
| EBIT | -141.81M | -171.66M | -300.54M | -582.02M |
| Interest Income | 3.20M | 3.19M | 4.62M | 95.98M |
| Pretax Income | -170.8M | -172.89M | -273.97M | -857.11M |
| Income Tax | -3.86M | 4.03M | -242.81M | -8.57M |
| Minority Interest | 0 | 0 | 0 | 0 |
| Net Income | -166.94M | -176.91M | -31.16M | -848.53M |
| Net Income Basic | -166.94M | -176.91M | -31.16M | -848.53M |
Exact Sciences Corp. income statements (2020) (USD)
| October 2020 | September 2020 | June 2020 | March 2020 | March 2020 | |
|---|---|---|---|---|---|
| Total Revenue | 408.36M | 408.36M | 268.87M | 347.82M | 347.82M |
| Cost of Revenue | 95.06M | 118.49M | 101.32M | 104.95M | 104.95M |
| Gross Profit | 313.30M | 289.87M | 167.55M | 242.88M | 242.88M |
| Research & Development | 31.47M | 31.47M | 32.67M | 43.51M | 43.51M |
| Selling General & Admin | 252.07M | 252.07M | 225.55M | 256.74M | 256.74M |
| Operating Expense | 402.03M | 402.03M | 359.54M | 405.19M | 405.19M |
| Operating Income | 6.33M | 6.33M | -90.67M | -57.37M | -57.37M |
| Other Income Expense Net | 0 | -230.73M | 3.67M | -50.06M | -50.06M |
| EBIT | 6.33M | 6.33M | -90.67M | -57.37M | -57.37M |
| Interest Income | 23.58M | 23.58M | 22.91M | 17.20M | 17.20M |
| Pretax Income | -224.39M | -224.39M | -87.01M | -107.43M | -107.43M |
| Income Tax | -4.51M | -4.51M | -867K | -1.73M | -1.73M |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Net Income | -219.88M | -219.88M | -86.14M | -105.7M | -105.7M |
| Net Income Basic | -219.88M | -219.88M | -86.14M | -105.7M | -105.7M |
Exact Sciences Corp. income statements (2019) (USD)
| December 2019 | September 2019 | June 2019 | March 2019 | |
|---|---|---|---|---|
| Total Revenue | 295.58M | 218.81M | 199.87M | 162.04M |
| Cost of Revenue | 84.20M | 52.76M | 51.56M | 43.25M |
| Gross Profit | 211.38M | 166.05M | 148.31M | 118.79M |
| Research & Development | 43.22M | 34.95M | 30.20M | 32.02M |
| Selling General & Admin | 210.60M | 166.76M | 151.92M | 154.97M |
| Operating Expense | 338.02M | 254.47M | 233.69M | 230.24M |
| Operating Income | -42.45M | -35.66M | -33.82M | -68.19M |
| Other Income Expense Net | -64.24M | -4.12M | -5.04M | -15.34M |
| EBIT | -42.45M | -35.66M | -33.82M | -68.19M |
| Interest Income | 13.69M | 13.21M | 12.71M | 21.99M |
| Pretax Income | -106.68M | -39.78M | -38.86M | -83.53M |
| Income Tax | -184.63M | 683K | -443K | -470K |
| Minority Interest | 0 | 0 | 0 | 0 |
| Net Income | 77.95M | -40.46M | -38.42M | -83.06M |
| Net Income Basic | 77.95M | -40.46M | -38.42M | -83.06M |
Exact Sciences Corp. income statements (2018) (USD)
| December 2018 | September 2018 | June 2018 | March 2018 | |
|---|---|---|---|---|
| Total Revenue | 142.98M | 118.29M | 102.89M | 90.30M |
| Cost of Revenue | 38.16M | 30.02M | 26.89M | 22.91M |
| Gross Profit | 104.82M | 88.27M | 76.01M | 67.38M |
| Research & Development | 20.93M | 17.63M | 14.71M | 14.94M |
| Selling General & Admin | 133.21M | 111.57M | 94M | 88.98M |
| Operating Expense | 192.30M | 159.22M | 135.60M | 126.82M |
| Operating Income | -49.32M | -40.93M | -32.7M | -36.53M |
| Other Income Expense Net | -4.65M | -4.41M | -3.69M | -2.84M |
| EBIT | -49.32M | -40.93M | -32.7M | -36.53M |
| Interest Income | 10.97M | 10.70M | 8.60M | 6.51M |
| Pretax Income | -53.97M | -45.34M | -36.39M | -39.37M |
| Income Tax | 7K | 27K | -1K | 59K |
| Minority Interest | 0 | 0 | 0 | 0 |
| Net Income | -53.97M | -45.36M | -36.39M | -39.42M |
| Net Income Basic | -53.97M | -45.36M | -36.39M | -39.42M |
Exact Sciences Corp. income statements (2017) (USD)
| December 2017 | September 2017 | June 2017 | |
|---|---|---|---|
| Total Revenue | 87.41M | 72.57M | 57.65M |
| Cost of Revenue | 23.50M | 20.73M | 17.99M |
| Gross Profit | 63.91M | 51.85M | 39.66M |
| Research & Development | 12.68M | 11.73M | 9.74M |
| Selling General & Admin | 74.37M | 68.53M | 61.34M |
| Operating Expense | 110.54M | 100.99M | 89.07M |
| Operating Income | -23.13M | -28.41M | -31.42M |
| Other Income Expense Net | 1.27M | 1.28M | 629K |
| EBIT | -23.13M | -28.41M | -31.42M |
| Interest Income | 51K | 51K | 54K |
| Pretax Income | -21.86M | -27.13M | -30.79M |
| Income Tax | -99K | -231K | N.A |
| Minority Interest | 0 | 0 | 0 |
| Net Income | -21.76M | -26.9M | -30.79M |
| Net Income Basic | -21.76M | -26.9M | -30.79M |
Exact Sciences Corp. balance sheet (2023) (USD)
| February 2023 | |
|---|---|
| Current Cash | 632.06M |
| Receivables | 158.04M |
| Inventory | 118.26M |
| Current Assets | 0.98B |
| Other Current Assets | 73.90M |
| Short Term Investments | 73.90M |
| Long Term Investments | 5.24B |
| Property/Plant Equipment | 684.76M |
| Good Will | N.A |
| Intangible Assets | 1.96B |
| Tangible Assets (Net) | -1.26B |
| Other Assets | 90.58M |
| Total Assets | 6.23B |
| Accounts Payable | 74.92M |
| Other Current Liabilities | 337.83M |
| Total Current Liabilities | 412.75M |
| Total Liabilities | 3.18B |
| Long Term Debt | 2.24B |
| Current Long Term Debt | 0 |
| Minority Interest | 0 |
| Common Stock | 177.63M |
| Treasury Stock | 0 |
| Retained Earnings | -3.27B |
| Capital Surplus | N.A |
| Shareholder Equity | 3.04B |
| Other Liabilities | N.A |
Exact Sciences Corp. balance sheet (2022) (USD)
| August 2022 | August 2022 | April 2022 | February 2022 | |
|---|---|---|---|---|
| Current Cash | 728.04M | 728.04M | 816.98M | 1.03B |
| Receivables | 186.54M | 186.54M | 205.63M | 216.65M |
| Inventory | 115.17M | 115.17M | 112.96M | 104.99M |
| Current Assets | 1.10B | 1.10B | 1.22B | 1.43B |
| Other Current Assets | 71.88M | 71.88M | 79.58M | 74.12M |
| Short Term Investments | 71.88M | 71.88M | 79.58M | 74.12M |
| Long Term Investments | 5.34B | 5.34B | 5.28B | 5.26B |
| Property/Plant Equipment | 663.65M | 663.65M | 622.61M | 580.25M |
| Good Will | N.A | N.A | N.A | N.A |
| Intangible Assets | 2.05B | 2.05B | 2.07B | 2.09B |
| Tangible Assets (Net) | -1.18B | -1.18B | -1.15B | -1.04B |
| Other Assets | 96.68M | 96.68M | 77.48M | 74.59M |
| Total Assets | 6.44B | 6.44B | 6.49B | 6.68B |
| Accounts Payable | 84.17M | 84.17M | 66.47M | 67.83M |
| Other Current Liabilities | 359.16M | 359.16M | 414.48M | 449.24M |
| Total Current Liabilities | 443.33M | 443.33M | 480.95M | 517.07M |
| Total Liabilities | 3.23B | 3.23B | 3.23B | 3.30B |
| Long Term Debt | 2.23B | 2.23B | 2.18B | 2.18B |
| Current Long Term Debt | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 |
| Common Stock | 176.36M | 176.36M | 174.42M | 171.35M |
| Treasury Stock | 0 | 0 | 0 | 0 |
| Retained Earnings | -2.99B | -2.99B | -2.82B | -2.64B |
| Capital Surplus | N.A | N.A | N.A | N.A |
| Shareholder Equity | 3.21B | 3.21B | 3.26B | 3.39B |
| Other Liabilities | N.A | N.A | N.A | N.A |
Exact Sciences Corp. balance sheet (2021) (USD)
| November 2021 | July 2021 | May 2021 | February 2021 | |
|---|---|---|---|---|
| Current Cash | 1.22B | 1.31B | 1.38B | 1.84B |
| Receivables | 249.57M | 226.54M | 256.14M | 233.19M |
| Inventory | 95.17M | 89.81M | 89.03M | 92.27M |
| Current Assets | 1.62B | 1.67B | 1.78B | 2.20B |
| Other Current Assets | 52.39M | 45.28M | 52.17M | 33.16M |
| Short Term Investments | 52.39M | 45.28M | 52.17M | 33.16M |
| Long Term Investments | 5.04B | 5.06B | 4.96B | 2.73B |
| Property/Plant Equipment | 524.20M | 501.91M | 482.74M | 450.68M |
| Good Will | N.A | N.A | N.A | N.A |
| Intangible Assets | 2.04B | 2.09B | 2.07B | 848.43M |
| Tangible Assets (Net) | -829.9M | -772.54M | -608.85M | 737.39M |
| Other Assets | 59.24M | 54.66M | 56.95M | 63.77M |
| Total Assets | 6.65B | 6.72B | 6.73B | 4.93B |
| Accounts Payable | 41.72M | 36.59M | 34.70M | 35.71M |
| Other Current Liabilities | 354.09M | 324.83M | 280.06M | 283.35M |
| Total Current Liabilities | 710.23M | 675.70M | 628.91M | 575.84M |
| Total Liabilities | 3.20B | 3.17B | 3.09B | 2.10B |
| Long Term Debt | 1.89B | 1.89B | 1.89B | 1.34B |
| Current Long Term Debt | 314.42M | 314.28M | 314.15M | 256.78M |
| Minority Interest | 0 | 0 | 0 | 0 |
| Common Stock | 171.98M | 171.49M | 169.43M | 151.14M |
| Treasury Stock | 0 | 0 | 0 | 0 |
| Retained Earnings | -2.42B | -2.25B | -2.08B | -1.97B |
| Capital Surplus | N.A | N.A | N.A | N.A |
| Shareholder Equity | 3.46B | 3.56B | 3.65B | 2.82B |
| Other Liabilities | N.A | N.A | N.A | N.A |
Exact Sciences Corp. balance sheet (2020) (USD)
| October 2020 | September 2020 | June 2020 | March 2020 | March 2020 | |
|---|---|---|---|---|---|
| Current Cash | 1.28B | 806.68M | 703.93M | 701.05M | 701.05M |
| Receivables | 206.61M | 206.61M | 163.61M | 140.05M | 140.05M |
| Inventory | 80.43M | 80.43M | 82.22M | 69.42M | 69.42M |
| Current Assets | 1.61B | 1.61B | 1.50B | 1.48B | 1.48B |
| Other Current Assets | 36.59M | 34.99M | 34.78M | 42.13M | 42.13M |
| Short Term Investments | 36.59M | 476.32M | 518.73M | 530.06M | 530.06M |
| Long Term Investments | 2.75B | 291K | 282K | N.A | N.A |
| Property/Plant Equipment | 456.46M | 586.29M | 596.19M | 589.85M | 589.85M |
| Good Will | N.A | N.A | N.A | N.A | N.A |
| Intangible Assets | 871.66M | 871.66M | 1.11B | 1.13B | 1.13B |
| Tangible Assets (Net) | 227.77M | -1.1B | -1.14B | -1.11B | -1.11B |
| Other Assets | 52.12M | 50.33M | 22.12M | 20.04M | 20.04M |
| Total Assets | 4.35B | 4.35B | 4.47B | 4.46B | 4.46B |
| Accounts Payable | 26.06M | 26.06M | 31M | 38.05M | 38.05M |
| Other Current Liabilities | 225.45M | 210.21M | 178.99M | 170.71M | 170.71M |
| Total Current Liabilities | 252.83M | 252.83M | 222.27M | 243.58M | 243.58M |
| Total Liabilities | 2.02B | 2.02B | 1.96B | 1.92B | 1.92B |
| Long Term Debt | 1.58B | 1.71B | 1.68B | 1.63B | 1.63B |
| Current Long Term Debt | 1.32M | 5.32M | 1.32M | 24.57M | 24.57M |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Common Stock | 3.87B | 150.37M | 149.98M | 149.45M | 149.45M |
| Treasury Stock | 0 | N.A | N.A | N.A | N.A |
| Retained Earnings | -1.53B | -1.53B | -1.31B | -1.23B | -1.23B |
| Capital Surplus | N.A | 3.87B | 3.82B | 3.76B | 3.76B |
| Shareholder Equity | 2.34B | 2.34B | 2.51B | 2.54B | 2.54B |
| Other Liabilities | N.A | N.A | N.A | N.A | N.A |
Exact Sciences Corp. balance sheet (2019) (USD)
| December 2019 | September 2019 | June 2019 | March 2019 | |
|---|---|---|---|---|
| Current Cash | 177.25M | 1.03B | 205.06M | 285.20M |
| Receivables | 130.67M | 82.20M | 63.90M | 56.10M |
| Inventory | 61.72M | 53.67M | 47.78M | 44.27M |
| Current Assets | 556.96M | 1.32B | 1.37B | 1.41B |
| Other Current Assets | 39.31M | 21.96M | 23.69M | 22.45M |
| Short Term Investments | 146.40M | 126.21M | 1.03B | 1B |
| Long Term Investments | N.A | N.A | N.A | N.A |
| Property/Plant Equipment | 581.77M | 389.63M | 357.20M | 313.43M |
| Good Will | N.A | N.A | N.A | N.A |
| Intangible Assets | 1.14B | 27.11M | 27.77M | 28.33M |
| Tangible Assets (Net) | -1.28B | 680.09M | 697.49M | 709.13M |
| Other Assets | 18.79M | 2.17M | 4.90M | 1.29M |
| Total Assets | 3.51B | 1.76B | 1.78B | 1.77B |
| Accounts Payable | 25.97M | 19.16M | 19.90M | 17.55M |
| Other Current Liabilities | 199.60M | 139.39M | 156.85M | 144.68M |
| Total Current Liabilities | 236.49M | 480.69M | 492.46M | 167.66M |
| Total Liabilities | 1.22B | 1.01B | 1.02B | 0.99B |
| Long Term Debt | 0.95B | 516.88M | 517.72M | 819.10M |
| Current Long Term Debt | 834K | 316.24M | 312.01M | 21K |
| Minority Interest | 0 | 0 | 0 | 0 |
| Common Stock | 147.63M | 129.82M | 129.36M | 129.08M |
| Treasury Stock | N.A | N.A | N.A | N.A |
| Retained Earnings | -1.12B | -1.2B | -1.16B | -1.12B |
| Capital Surplus | 3.41B | 1.95B | 1.92B | 1.89B |
| Shareholder Equity | 2.29B | 748.28M | 765.53M | 776.94M |
| Other Liabilities | N.A | N.A | N.A | N.A |
Exact Sciences Corp. balance sheet (2018) (USD)
| December 2018 | September 2018 | June 2018 | March 2018 | |
|---|---|---|---|---|
| Current Cash | 160.43M | 161.71M | 225.66M | 148.70M |
| Receivables | 44.24M | 41.92M | 36.27M | 34.58M |
| Inventory | 39.15M | 38.62M | 35.41M | 32.38M |
| Current Assets | 1.23B | 1.29B | 1.31B | 1.12B |
| Other Current Assets | 18.90M | 21.93M | 14.57M | 10.97M |
| Short Term Investments | 0.96B | 1.02B | 1B | 893.47M |
| Long Term Investments | N.A | N.A | N.A | N.A |
| Property/Plant Equipment | 245.26M | 188.49M | 140.47M | 103.45M |
| Good Will | N.A | N.A | N.A | N.A |
| Intangible Assets | 29M | 20.51M | 21.13M | 21.56M |
| Tangible Assets (Net) | 613.27M | 688.92M | 716.57M | 663.36M |
| Other Assets | 1.32M | 9.02M | 8.77M | 9.92M |
| Total Assets | 1.52B | 1.51B | 1.48B | 1.26B |
| Accounts Payable | 28.14M | 32.74M | 10.99M | 12.27M |
| Other Current Liabilities | 106.04M | 71.60M | 65.08M | 58.97M |
| Total Current Liabilities | 136.59M | 106.74M | 82.96M | 73.33M |
| Total Liabilities | 843.08M | 792.85M | 738.26M | 569.90M |
| Long Term Debt | 696.58M | 673.42M | 648.80M | 490.93M |
| Current Long Term Debt | 8K | N.A | 4.59M | 183K |
| Minority Interest | 0 | 0 | 0 | 0 |
| Common Stock | 123.19M | 122.89M | 122.60M | 121.87M |
| Treasury Stock | N.A | N.A | N.A | N.A |
| Retained Earnings | -1.04B | -0.98B | -0.94B | -0.9B |
| Capital Surplus | 1.72B | 1.70B | 1.68B | 1.59B |
| Shareholder Equity | 680.94M | 716.73M | 744.39M | 687.02M |
| Other Liabilities | N.A | N.A | N.A | N.A |
Exact Sciences Corp. balance sheet (2017) (USD)
| December 2017 | September 2017 | June 2017 | |
|---|---|---|---|
| Current Cash | 77.49M | 50.84M | 180.41M |
| Receivables | 26.42M | 24.55M | 22.59M |
| Inventory | 26.03M | 18.06M | 12.41M |
| Current Assets | 487.22M | 513.69M | 526.13M |
| Other Current Assets | 5.36M | 7.25M | 5.57M |
| Short Term Investments | 347.22M | 411.68M | 303.85M |
| Long Term Investments | N.A | N.A | N.A |
| Property/Plant Equipment | 79.99M | 55.71M | 42.05M |
| Good Will | N.A | N.A | N.A |
| Intangible Assets | 22.16M | 9.37M | 9.70M |
| Tangible Assets (Net) | 492.76M | 527.14M | 540.69M |
| Other Assets | 7.20M | 8.42M | 4.72M |
| Total Assets | 598.56M | 587.18M | 582.60M |
| Accounts Payable | 16.14M | 8.77M | 2.24M |
| Other Current Liabilities | 50.11M | 39.24M | 27.58M |
| Total Current Liabilities | 68.12M | 49.69M | 31.29M |
| Total Liabilities | 78.14M | 60.04M | 41.91M |
| Long Term Debt | 4.27M | 4.51M | 4.55M |
| Current Long Term Debt | 182K | 180K | 178K |
| Minority Interest | 0 | 0 | 0 |
| Common Stock | 120.50M | 119.59M | 119.05M |
| Treasury Stock | N.A | N.A | N.A |
| Retained Earnings | -860.61M | -838.85M | -811.95M |
| Capital Surplus | 1.38B | 1.37B | 1.35B |
| Shareholder Equity | 520.42M | 527.14M | 540.69M |
| Other Liabilities | N.A | N.A | N.A |
Exact Sciences Corp. cash flow (2023) (USD)
| February 2023 | |
|---|---|
| Net Income | -127.75M |
| Depreciation | 49.48M |
| Changes in Receivables | 158.04M |
| Changes in Inventories | 118.26M |
| Cash Change | 632.06M |
| Cash Flow | 52.04M |
| Capital Expenditures | -72.88M |
| Investments | N.A |
| Investing Activity (other) | N.A |
| Total Investing Cash Flows | -58.16M |
| Dividends Paid | N.A |
| Net Borrowings | 1.53B |
| Other Financing Cash Flows | N.A |
| Cash Flow Financing | 10.10M |
| Exchange Rate Effect | N.A |
Exact Sciences Corp. cash flow (2022) (USD)
| November 2022 | August 2022 | April 2022 | |
|---|---|---|---|
| Net Income | -148.76M | -166.06M | 407M |
| Depreciation | 48.57M | 51.86M | 525M |
| Changes in Receivables | 189.21M | 186.54M | 2.43B |
| Changes in Inventories | 114.70M | 115.17M | 0 |
| Cash Change | 669.11M | 728.04M | 4.16B |
| Cash Flow | -40.93M | -60.92M | 323M |
| Capital Expenditures | -44.64M | -63.33M | -85M |
| Investments | N.A | N.A | N.A |
| Investing Activity (other) | N.A | N.A | N.A |
| Total Investing Cash Flows | 65.01M | 21.66M | 529M |
| Dividends Paid | N.A | N.A | N.A |
| Net Borrowings | 1.49B | 1.43B | 9.65B |
| Other Financing Cash Flows | N.A | N.A | N.A |
| Cash Flow Financing | 235K | 63.41M | -587M |
| Exchange Rate Effect | N.A | N.A | N.A |
Exact Sciences Corp. cash flow (2021) (USD)
| November 2021 | |
|---|---|
| Net Income | -166.94M |
| Depreciation | 46.20M |
| Changes in Receivables | 249.57M |
| Changes in Inventories | 95.17M |
| Cash Change | 1.22B |
| Cash Flow | -40.77M |
| Capital Expenditures | -38.87M |
| Investments | N.A |
| Investing Activity (other) | N.A |
| Total Investing Cash Flows | -49.24M |
| Dividends Paid | N.A |
| Net Borrowings | 0.93B |
| Other Financing Cash Flows | N.A |
| Cash Flow Financing | 81K |
| Exchange Rate Effect | N.A |
Exact Sciences Corp. cash flow (2020) (USD)
| October 2020 | September 2020 | June 2020 | March 2020 | |
|---|---|---|---|---|
| Net Income | -219.88M | -219.88M | -86.14M | -105.7M |
| Depreciation | 123.54M | 47.32M | 37.73M | 49.54M |
| Changes in Receivables | 43M | -43M | -23.56M | -9.38M |
| Changes in Inventories | -1.79M | 1.79M | -12.79M | -7.47M |
| Cash Change | 60.35M | 102.76M | 2.87M | 523.81M |
| Cash Flow | 25.08M | 82.91M | -4.08M | -47.62M |
| Capital Expenditures | -47.78M | -14.33M | -20.77M | -12.69M |
| Investments | N.A | 41.50M | 14.42M | -386.03M |
| Investing Activity (other) | N.A | -10.34M | -186K | -330K |
| Total Investing Cash Flows | -244K | 16.83M | -6.38M | -405.85M |
| Dividends Paid | N.A | N.A | N.A | N.A |
| Net Borrowings | 259.34M | -1.14M | -2.47M | 0.97B |
| Other Financing Cash Flows | N.A | -312K | 9.17M | N.A |
| Cash Flow Financing | 1B | 3.02M | 13.34M | 0.98B |
| Exchange Rate Effect | N.A | N.A | N.A | N.A |
Exact Sciences Corp. cash flow (2019) (USD)
| December 2019 | September 2019 | June 2019 | March 2019 | |
|---|---|---|---|---|
| Net Income | 77.95M | -40.46M | -38.42M | -83.06M |
| Depreciation | 28.82M | 10.08M | 8.80M | 7.98M |
| Changes in Receivables | -48.47M | -18.3M | -7.81M | -11.86M |
| Changes in Inventories | -4.52M | -5.89M | -3.51M | -5.12M |
| Cash Change | -856.81M | 829.28M | -80.14M | 124.77M |
| Cash Flow | -24.57M | -29.08M | 17.16M | -74.41M |
| Capital Expenditures | -40.3M | -51.67M | -69.03M | -10.8M |
| Investments | 181.24M | 0.91B | -33.64M | -30.27M |
| Investing Activity (other) | -1.85M | N.A | N.A | N.A |
| Total Investing Cash Flows | -834.77M | 857.44M | -102.67M | -41.07M |
| Dividends Paid | N.A | N.A | N.A | N.A |
| Net Borrowings | -4.11M | -2K | -34K | 236.48M |
| Other Financing Cash Flows | -4.17M | -409K | 4.14M | N.A |
| Cash Flow Financing | 2.51M | 0.98M | 5.45M | 240.13M |
| Exchange Rate Effect | 28K | -66K | -82K | 120K |
Exact Sciences Corp. cash flow (2018) (USD)
| December 2018 | September 2018 | June 2018 | March 2018 | |
|---|---|---|---|---|
| Net Income | -53.97M | -45.36M | -36.39M | -39.42M |
| Depreciation | 6.89M | 6.16M | 5.14M | 4.89M |
| Changes in Receivables | -2.32M | -5.65M | -1.69M | -8.16M |
| Changes in Inventories | -139K | -3.21M | -3.03M | -6.35M |
| Cash Change | -1.28M | -63.96M | 76.97M | 71.20M |
| Cash Flow | -1.24M | -4.05M | -25.51M | -38.52M |
| Capital Expenditures | -52.55M | -53.63M | -29.11M | -15.39M |
| Investments | 61.04M | -25.36M | -101.67M | -547.34M |
| Investing Activity (other) | N.A | N.A | N.A | N.A |
| Total Investing Cash Flows | -9.42M | -78.99M | -130.78M | -562.73M |
| Dividends Paid | N.A | N.A | N.A | N.A |
| Net Borrowings | 6.86M | 18.34M | 226.36M | 671.05M |
| Other Financing Cash Flows | N.A | N.A | N.A | N.A |
| Cash Flow Financing | 9.35M | 19.07M | 233.28M | 672.44M |
| Exchange Rate Effect | 24K | 10K | -18K | 20K |
Exact Sciences Corp. cash flow (2017) (USD)
| December 2017 | September 2017 | June 2017 | |
|---|---|---|---|
| Net Income | -21.76M | -26.9M | -30.79M |
| Depreciation | 4.40M | 4.11M | 3.75M |
| Changes in Receivables | -1.87M | -1.96M | -6.38M |
| Changes in Inventories | -7.96M | -5.65M | -4.55M |
| Cash Change | 26.65M | -129.57M | 141.20M |
| Cash Flow | -764K | -5.45M | -31.87M |
| Capital Expenditures | -36.33M | -15.82M | -14.35M |
| Investments | 60.97M | -107.78M | -68.45M |
| Investing Activity (other) | N.A | N.A | N.A |
| Total Investing Cash Flows | 24.65M | -126.6M | -82.79M |
| Dividends Paid | N.A | N.A | N.A |
| Net Borrowings | -44K | -44K | -42K |
| Other Financing Cash Flows | N.A | -1.63M | 1.63M |
| Cash Flow Financing | 2.72M | 2.46M | 255.78M |
| Exchange Rate Effect | 46K | 16K | 89K |
Exact Sciences Corp. dividends (USD)
Total Valuation
Exact Sciences Corp. has a market cap or net worth of $15.13 billion. The enterprise value is $16.79 billion.
Market Cap
15.13B
Enterprise Value
16.79B
Important Dates
Earnings Date
Aug 1, 2023
Ex-Dividend Date
n.a
Share Statistics
Exact Sciences Corp. has 180.48 million shares outstanding.
Shares Outstanding
180.48M
Float
n.a
Valuation Ratios
The trailing PE ratio is -29.2829 and the forward PE ratio is -31.5767. Exact Sciences Corp.'s PEG ratio is -0.8995.
PE Ratio
-29.2829
Forward PE
-31.5767
PS Ratio
6.8800
PB Ratio
4.9500
PEG Ratio
-0.8995
Stock Price Statistics
The stock price has increased by 0.6934%. The beta is 1.7121, so Exact Sciences Corp.'s price volatility has been higher than the market average.
Beta (1Y)
1.7121
52-Week Price Change
+0.6934%
50-Day Moving Average
73.47
200-Day Moving Average
62.60
Average Volume (30 Days)
2.13M
Income Statement
In the last 12 months, Exact Sciences Corp. had revenue of $2.20 billion and earned $1.60 billion in profits. Earnings per share was $-2.91.
Revenue
2.20B
Gross Profit
1.60B
EBITDA
-368.61M
Earnings per Share
-2.91
About
Ticker Symbol
EXAS
Reporting Currency
USD
Key Executives
Hooker Ana
SVP, Operations
Berger Barry M
Chief Medical Officer
Conroy Kevin T
President and CEO
ARORA MANEESH
COO
LIDGARD GRAHAM PETER
Chief Science Officer
COWARD D SCOTT
SVP and General Counsel
Elliott Jeffrey Thomas
Chief Financial Officer
Hoof Torsten
General Manager, International